Last updated: May 23, 2026
Demeclocycline hydrochloride is an older tetracycline antibiotic used for indications such as nephrogenic diabetes insipidus (NDI). Supply is fragmented across generic manufacturers and API producers. In the US and EU, commercial availability typically tracks US generic firms plus contract manufacturing/APIs from China and India, with limited brand-level domestic manufacturing.
Which companies supply demeclocycline hydrochloride API and finished dosage forms?
The market for demeclocycline hydrochloride is dominated by generic supply chains, with APIs sourced through global producers and finished tablets distributed by generic labelers. Most finished-goods listings are handled by multiple distributors and wholesalers rather than a single dominant manufacturer.
API supply: where demeclocycline hydrochloride is usually made
Demeclocycline hydrochloride API production is generally concentrated in Asian contract manufacturers that supply US and EU generic plants through trading and licensing arrangements. Typical sourcing route for finished products is:
API producer (often China/India) → API import and testing → finished-dose manufacturer (US/EU) → US wholesaler and pharmacy distribution.
Finished dosage form supply: who sells tablets
Demeclocycline hydrochloride is primarily sold as oral tablets (commonly in 300 mg strength in many markets). Finished-goods suppliers in practice include:
- US generic drug manufacturers that list demeclocycline hydrochloride tablets on US distribution networks
- EU generic manufacturers and parallel traders
- Pharmacy chain private-label arrangements in some regions (less common for this legacy product)
Who are the most common distributors for demeclocycline hydrochloride tablets in the US?
In the US, distribution is generally routed through wholesalers and specialty distributors that carry generic legacy antibiotics. Typical channels include:
- National wholesalers (primary distribution)
- Regional wholesalers (secondary distribution)
- Authorized distributor networks for hospital pharmacy procurement
Exact distributor “brand” is a function of current inventory and purchase contracts, so commercial availability often appears as:
- “generic demeclocycline hydrochloride” across multiple NDCs
- multiple labelers under the same underlying API supply chain
How do you identify authorized US suppliers and current labelers for demeclocycline hydrochloride?
Use supply verification paths that confirm both legal authorization and current inventory:
- FDA “Drugs@FDA” and NDC directory for labeler and product listing
- Orange Book listings for approved products and patents (where applicable)
- DSCSA verification records through trading partner systems (for authorized chain-of-custody)
This is the most reliable way to map “supplier” in a compliance sense, since “supplier” can mean labeler, manufacturer, API source, or distributor.
What supply risks affect demeclocycline hydrochloride availability?
Legacy generics face supply constraints that drive procurement volatility:
- Concentrated API manufacturing for older molecules
- Aging production lines and periodic plant downtimes
- Lower commercial incentives versus newer therapies
- Regulatory quality events that can force temporary suspension or slow requalification
In practice, these risks show up as:
- inconsistent wholesaler fill rates
- short-dated inventory during demand spikes
- NDC-level shortages where some labelers maintain supply and others do not
Which regions have the most reliable supply coverage for demeclocycline hydrochloride?
- US: Finished-dose production and distribution are through generic manufacturers with imported API.
- EU/UK: Similar model, with finished products manufactured locally or imported, and API from global suppliers.
- China and India: Common API production footprint that supports international finished-goods supply.
Reliability depends on current inspections and ongoing production continuity at the API plant and the finished-dose facility.
How to qualify a demeclocycline hydrochloride supplier for regulated procurement
For sourcing decisions in hospitals, GPOs, and pharma procurement, qualification usually includes:
- Verification of FDA approval status for the finished dosage form
- Confirmation of GMP status for the manufacturing site
- CoA and impurity profile alignment with the relevant monograph (USP or pharmacopeia used)
- DSCSA-compliant traceability (US context)
- Audit rights and change-control transparency (API source changes are a key trigger)
What documentation should procurement request from a demeclocycline hydrochloride supplier?
Procurement packages commonly include:
- Certificate of Analysis (batch-specific) including assay and relevant impurities
- GMP/GDP documentation for manufacturing and distribution chain
- Labeling compliance for the target market
- Stability data and shelf-life remaining policy
- Change history for formulation, manufacturing process, and API supplier
How does demeclocycline hydrochloride supplier landscape compare with other tetracyclines?
Compared with higher-volume tetracyclines (e.g., doxycycline, minocycline), demeclocycline typically has:
- fewer active competitors per strength/market
- more “legacy generic” behavior, with periodic shortages driven by API plant capacity
- smaller commercial scale that makes supplier switching more disruptive
Key Takeaways
- Demeclocycline hydrochloride supply is primarily a generic legacy market, with finished tablets supplied by multiple generic labelers and APIs typically sourced globally.
- In regulated procurement, “supplier” should be defined as the approved finished-dose labeler/manufacturer plus the verified API and manufacturing sites behind it.
- Availability risk is concentrated in API and a limited number of active manufacturing lines, which can cause NDC-level shortages.
FAQs
1) How can I confirm the US labeler/manufacturer for a specific demeclocycline hydrochloride NDC?
Use FDA Drugs@FDA and the NDC directory to map the NDC to the approved product and labeler, then match the manufacturing site information from the application record.
2) Are there commonly used strengths and dosage forms for demeclocycline hydrochloride tablets?
The market is primarily oral tablets, with 300 mg commonly seen in practice; specific strengths depend on country and current NDC portfolio.
3) What makes demeclocycline hydrochloride more prone to shortages than newer antibiotics?
Lower market volume and concentrated API supply make it more sensitive to manufacturing disruptions and regulatory or quality events.
4) Can I substitute another tetracycline if demeclocycline hydrochloride is unavailable for NDI?
Substitution depends on indication, dosing, and clinical guidance; the patent and regulatory substitution pathway is not automatic across tetracyclines.
5) What is the fastest way to reduce procurement risk when sourcing demeclocycline hydrochloride?
Qualify multiple approved labelers/NDCs, lock allocations early, and require DSCSA-compliant traceability plus batch-level CoA review.
References
- U.S. Food and Drug Administration. Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
- U.S. Food and Drug Administration. NDC Directory. https://ndclist.com/ (NDC Directory access links may vary)
- U.S. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
